TY  - JOUR
T1  - STudies shed light on risks and trends in pediatric antipsychotic prescribing
AU  - Kuehn BM
Y1  - 2010/05/19
N1  - 10.1001/jama.2010.596
JO  - JAMA
SP  - 1901
EP  - 1903
VL  - 303
IS  - 19
N2  - 
Until recently, only two atypical antipsychotic drugs were approved by the US Food and Drug Administration (FDA) for use in children and adolescents. Risperidone was approved for use in patients aged 13 to 17 years with schizophrenia, patients aged 10 to 17 years for manic or mixed episodes associated with bipolar disorder, and patients aged 5 to 16 years for irritability associated with autism. Aripiprazole was approved to treat schizophrenia in individuals aged 13 to 17 years, and for use alone or as an adjunct to lithium or valproate in individuals aged 10 to 17 years with bipolar mania.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2010.596
UR  - http://dx.doi.org/10.1001/jama.2010.596
ER  -